| Mr Harry M Lawrence, MD | |
|
1042 E 3rd St, Ste 102, Chattanooga, TN 37403-2167 | |
| (423) 265-1651 | |
| (423) 756-0050 |
| Full Name | Mr Harry M Lawrence |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1042 E 3rd St, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053317925 | NPI | - | NPPES |
| 00061894A | Other | GA | GA MEDICAID |
| 3144956 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD 2936 (Tennessee) | Primary |
| Entity Name | Molly R. Seal, M.d. P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427149665 PECOS PAC ID: 5496858466 Enrollment ID: O20070312000461 |
News Archive
Democratic presidential nominee Sen. Barack Obama (Ill.) on Monday released an advertisement that criticized Republican presidential nominee Sen. John McCain (Ariz.) for his views on health care and an article in which he discusses regulation of the health insurance market, the Boston Globe's "Political Intelligence" reports (Rhee, "Political Intelligence," Boston Globe, 9/22).
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.
Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Harry M Lawrence, MD 1042 E 3rd St, Ste 102, Chattanooga, TN 37403-2167 Ph: (423) 265-1651 | Mr Harry M Lawrence, MD 1042 E 3rd St, Ste 102, Chattanooga, TN 37403-2167 Ph: (423) 265-1651 |
News Archive
Democratic presidential nominee Sen. Barack Obama (Ill.) on Monday released an advertisement that criticized Republican presidential nominee Sen. John McCain (Ariz.) for his views on health care and an article in which he discusses regulation of the health insurance market, the Boston Globe's "Political Intelligence" reports (Rhee, "Political Intelligence," Boston Globe, 9/22).
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma.
Results of a recently completed clinical trial of a potential drug to treat Type 2 diabetes in children were announced Sunday [April 28] at the Pediatric Academic Societies 2019 meeting in Baltimore, Md. The New England Journal of Medicine also published the findings.
› Verified 9 days ago
Dr. Thomas M Reynolds, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2158 Northgate Park Ln, Suite 302, Chattanooga, TN 37415 Phone: 423-870-4900 Fax: 423-870-5889 | |
Carey Cameron Dozier, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 932 Spring Creek Rd, East Ridge Eye Center, Chattanooga, TN 37412 Phone: 423-894-1453 Fax: 423-899-8022 | |
Dr. John L Stone, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7300 Jarnigan Rd, Chattanooga, TN 37421 Phone: 423-664-3366 Fax: 423-531-2925 | |
Dr. Fred Marshall Gregg Iii, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 725 Glenwood Dr, Suite 892, Chattanooga, TN 37404 Phone: 423-624-3937 Fax: 423-629-6505 | |
Mrs. Molly R Seal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1042 E 3rd St, Ste 102, Chattanooga, TN 37403 Phone: 423-265-1651 Fax: 423-756-0050 | |
Dr. John Whitman Prenshaw, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7320 Shallowford Rd, Chattanooga, TN 37421 Phone: 423-894-5300 |